SON-080 May Decrease Chemotherapy-Induced Peripheral Neuropathy
The novel drug showed promise in helping to decrease chemotherapy-induced peripheral neuropathy for those who had received prior chemotherapy.
Exploring New Possibilities in Kidney Cancer Detection and Therapy
Experts discuss findings related to liquid biopsy profiling, later-line immunotherapy, and CDK4/6 inhibitor efficacy presented at the 2024 KCRS meeting.
FDA Accepts Resubmitted BLA for Cosibelimab in Advanced Skin Cancer
The FDA has set a Prescription Drug User Fee Act date of December 28, 2024, for cosibelimab in advanced or metastatic cutaneous squamous cell carcinoma.
Overcoming Physical and Social Barriers in the Lymphoma Field
Leaders from the lymphoma space highlight the importance of mentorship in establishing their careers and impart advice to women looking to advance theirs.
ODAC Votes in Favor of New Perioperative NSCLC Trial Design Proposals
Members agreed that perioperative regimen NSCLC trial designs should clarify the contribution of treatment during adjuvant and neoadjuvant therapy.
Ozuriftamab Vedotin Gains FDA Fast Track Designation for Recurrent SCCHN
Multiple confirmed responses in a phase 2 trial support the FDA designation for the experimental therapy in squamous cell carcinoma of the head and neck.